Close this search box.

Since the advent of biosimilars, experts and pundits have debated how reduced biosimilar prices will be and just much savings the follow-on drugs will offer. Now, new research sheds light on a different topic: who actually will experience the cost savings. And it doesn’t seem to be patients.

According to IMS Health’s new white paper, “Biosimilars: Who Saves?,” patients may see less than five percent of the $25 billion in savings that the Congressional Budget Office expects biosimilars to generate by 2018. The analysts found that:

With the biggest proportion of the savings staying with health plans and pharmacy benefit managers, the report posits, patients may fail to see the value of these therapies. In particular, those who already benefit from an innovator product may not be compelled to consider a biosimilar alternative. That, in turn, could mean limited use of biosimilars and less savings for the health care system.

For health plans to pass savings along to patients, they’ll need to look for more direct and creative mechanisms. The report suggests reducing premiums as one option.

To learn more, read “Biosimilars: Who Saves?”.

Leave a Reply

Your email address will not be published. Required fields are marked *